LQCL2215 - CMLE - PHARMACOGENOMIC TESTING FOR HIV-POSITIVE INDIVIDUALS-PHARMACOGENOMIC TESTING FOR HIV-POSITIVE INDIVIDUALS

PHARMACOGENOMIC TESTING FOR HIV-POSITIVE INDIVIDUALS

Pdf Summary

The document discusses molecular diagnostics in HIV-positive patients, focusing on factors contributing to virologic failure, antiretroviral medications, and drug resistance mutations. A case study of a patient with virologic failure due to non-adherence is highlighted, with details on pharmacogenomic testing revealing a resistance mutation (M184V) and hypersensitivity allele (HLA-B*5701). The importance of genotypic resistance testing and personalized treatment plans is emphasized to achieve virologic suppression. Pharmacogenomic testing can detect mutations affecting treatment efficacy and potential adverse reactions. Different classes of antiretrovirals and their mechanisms of action are explained, such as protease inhibitors blocking viral replication. Detection of resistance mutations is crucial for adjusting treatment regimens. The use of traditional and more sensitive sequencing methods is discussed for early mutation detection. Summary emphasizes the role of pharmacogenomics in improving patient outcomes and tailoring HIV treatment strategies effectively. The case study's outcome shows successful treatment adjustment leading to viral suppression. Overall, the document underscores the significance of molecular diagnostics and personalized medicine in managing HIV infection.

Keywords

molecular diagnostics

HIV-positive patients

virologic failure

antiretroviral medications

drug resistance mutations

pharmacogenomic testing

genotypic resistance testing

personalized treatment plans

antiretroviral classes

protease inhibitors